Prostate Cancer Screening

  • Donna P. Ankerst
  • Catherine M. Tangen
  • Ian M. ThompsonJr

Part of the Current Clinical Urology book series (CCU)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Trends in Prostate Cancer Screening

    1. Front Matter
      Pages 1-1
    2. Ruth Etzioni, Roman Gulati, Angela Mariotto
      Pages 3-14
    3. Richard J. Bryant, Freddie C. Hamdy
      Pages 15-21
    4. Robert K. Nam, Laurence H. Klotz
      Pages 23-33
    5. Sanjai K. Addla, Bob Djavan
      Pages 35-47
  3. Prostate-Specific Antigen

  4. Risk Assessment for Prostate Cancer

    1. Front Matter
      Pages 115-115
    2. Shahrokh F. Shariat, Michael W. Kattan
      Pages 117-180
    3. Kadee E Thompson, Amanda Reed, Dipen J Parekh
      Pages 205-211
    4. Kari Hemminki, Justo Lorenzo Bermejo
      Pages 213-222
  5. Recent Biomarkers for Prostate Cancer

    1. Front Matter
      Pages 224-224
    2. Jack Groskopf, Jack Schalken, Harry Rittenhouse
      Pages 233-241
    3. Rui Henrique, Carmen Jerónimo
      Pages 279-288
    4. Eddy S. Leman, Robert H. Getzenberg
      Pages 289-294
  6. Design and Methodologic Considerations in Biomarker Studies

    1. Front Matter
      Pages 296-296
    2. Ziding Feng, Jacob Kagan, Sudhir Srivastava
      Pages 297-306
  7. Building upon Recently Completed and Ongoing Prospective Trials

    1. Front Matter
      Pages 331-331
    2. Catherine M. Tangen, Phyllis J. Goodman
      Pages 333-348
    3. Amanda Black, Robert L. Grubb III, E David Crawford
      Pages 361-372
    4. Tineke Wolters, Fritz H. Schröder
      Pages 373-386
  8. Back Matter
    Pages 387-397

About this book


More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world’s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world’s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.


Biomarkers EPCA PSA PSA Screening Prevention Prostate Cancer Prostate Specific Antigen cancer prevention cancer screening classification screening

Editors and affiliations

  • Donna P. Ankerst
    • 1
    • 2
  • Catherine M. Tangen
    • 3
  • Ian M. ThompsonJr
    • 4
  1. 1.Department of MathematicsTechnical UniversityGarchingGermany
  2. 2.Associate Professor, Departments of Urology, and Epidemiology/BiostatisticsUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  3. 3.Member, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research CenterSeattleUK
  4. 4.Department of UrologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Bibliographic information

  • DOI
  • Copyright Information Humana Press 2009
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-60327-280-3
  • Online ISBN 978-1-60327-281-0
  • Buy this book on publisher's site